BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yuan J, Jiang C, Wang J, Chen CJ, Hao Y, Zhao G, Feng Z, Xie XQ. In Silico Prediction and Validation of CB2 Allosteric Binding Sites to Aid the Design of Allosteric Modulators. Molecules 2022;27. [PMID: 35056767 DOI: 10.3390/molecules27020453] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Sharma R, Singh S, Whiting ZM, Molitor M, Vernall AJ, Grimsey NL. Novel Cannabinoid Receptor 2 (CB2) Low Lipophilicity Agonists Produce Distinct cAMP and Arrestin Signalling Kinetics without Bias. IJMS 2023;24:6406. [DOI: 10.3390/ijms24076406] [Reference Citation Analysis]
2 Zhou H, Shan M, Qin LP, Cheng G. Reliable prediction of cannabinoid receptor 2 ligand by machine learning based on combined fingerprints. Comput Biol Med 2023;152:106379. [PMID: 36502694 DOI: 10.1016/j.compbiomed.2022.106379] [Reference Citation Analysis]
3 Persechino M, Hedderich JB, Kolb P, Hilger D. Allosteric modulation of GPCRs: From structural insights to in silico drug discovery. Pharmacology & Therapeutics 2022;237:108242. [DOI: 10.1016/j.pharmthera.2022.108242] [Reference Citation Analysis]
4 Ferranti AS, Foster DJ. Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits. Front Neurosci 2022;16:925792. [DOI: 10.3389/fnins.2022.925792] [Reference Citation Analysis]
5 Gado F, Ferrisi R, Polini B, Mohamed KA, Ricardi C, Lucarini E, Carpi S, Domenichini F, Stevenson LA, Rapposelli S, Saccomanni G, Nieri P, Ortore G, Pertwee RG, Ghelardini C, Di Cesare Mannelli L, Chiellini G, Laprairie RB, Manera C. Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands. J Med Chem 2022. [PMID: 35849804 DOI: 10.1021/acs.jmedchem.2c00582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]